Sugi Predict

Sugi Predict / Compounds / SCHEMBL3769121

SCHEMBL3769121

SCHEMBL3769121

O=[N+]([O-])c1cc2cn[nH]c2cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 6/20 0.53
▸ MAPT P10636 3/20 0.53
▸ CYP3A4 P08684 3/20 0.53
▸ LMNA P02545 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ MAOB P27338 1/20 0.53
▸ TSHR P16473 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ APEX1 P27695 1/20 0.45
▸ NOS3 P29474 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ NOS2 P35228 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ BLM P54132 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29680257 1.00 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL27228526 0.93 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL11680975 0.86 MAPT (0.59) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL29680531 0.81 NOS1 (0.54) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL1026662 0.81 NOS1 (0.54) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL2571492 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL30163112 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL16741277 0.80 CHEK1 (0.59) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL15534879 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15
SCHEMBL16751174 0.80 NOS1 (0.53) NOS1MAPTCYP3A4LMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116589410-B Synthesis method of 6-chloro-2-methyl-2H-indazole-5-amine 济南国鼎医药科技有限公司 2024-05-03 — — CN claimed
CN-117229216-A Preparation method of entecavir intermediate 重庆博腾制药科技股份有限公司 2023-12-15 — — CN claimed
CN-116924991-A Preparation method of 6-chloro-2-methyl-5-nitro-2H-indazole 北京白泽瑞成医药科技有限公司 2023-10-24 — — CN claimed
CN-116554106-A Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine 扬州市普林斯医药科技有限公司 2023-08-08 — — CN claimed
CN-116120236-A Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine 上海拓荒者医药科技有限公司 2023-05-16 — — CN claimed
CN-115677587-A Method for preparing 6-chloro-5-nitro-1-hydro-indazole 爱斯特（成都）生物制药股份有限公司 2023-02-03 — — CN claimed
CN-114835645-A Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine 上海昊泓生物科技有限公司 2022-08-02 — — CN claimed
CN-217060102-U 6-chlorine-5-nitro-1H-indazole thin-layer color development developing and developing cylinder 上海晋鲁医药科技有限公司 2022-07-26 — — CN claimed
CN-114605328-A Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine 汉瑞药业(荆门)有限公司 2022-06-10 — — CN claimed
CN-122029171-A Small molecule inhibitors of KRAS proteins 默沙东有限责任公司 2026-05-12 — — CN disclosed
EP-4709371-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2026-03-18 — — EP disclosed
US-20260035386-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS MERCK SHARP & DOHME LLC (US) 2026-02-05 — — US disclosed
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
WO-2025235740-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS MERCK SHARP & DOHME LLC (US) 2025-11-13 — — WO disclosed
EP-2435422-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-12-17 — — EP disclosed
US-8486933-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-07-16 — — US disclosed
CN-102459236-A Pyrimidine inhibitors of kinase activity ABBOTT LAB 2012-05-16 — — CN disclosed
WO-2010138578-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 — — WO disclosed
US-20100305112-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 — — US disclosed
US-4636456-A EXPOSURE, SILVER HALIDE EMULSIONS, HYDROQUINONE OR ESTER OR CARBONATE, DEVELOPMENT INHIBITORS FUJI PHOTO FILM CO., LTD. (JP) 1987-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305112-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 NOS1 2143/4885MAPT 2520/4885CYP3A4 3522/4885
US-20260035386-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS KRAS, NRAS, APC NOS1 547/4885MAPT 3891/4885CYP3A4 3548/4885
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS NOS1 4039/4885MAPT 4874/4885CYP3A4 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.